We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| IMV Inc | TSX:IMV | Toronto | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.12 | 0.60 | 0.70 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will present at the Spring Investor Summit and the HC Wainwright Global Life Sciences Conference during April 2019.
Details on each conference and presentation are as follows:
•
Venue: Spring Investor Summit, being held April 1-2, 2019
•
Date of Presentation: Monday, April 1
•
Time: 8:30 a.m. ET
•
Location: JW Marriott Hotel, Essex House, New York City
•
Venue: HC Wainwright Global Life Sciences Conference, being held April 7-9, 2019
•
Date: Tuesday, April 9, 2019
•
Time: 10:40 a.m. BST
•
Location: Stratton Suite, Grosvenor House, A JW Marriott Hotel, London, UK
There will be a live webcast of both of these presentations available in the events, presentations and webcasts section of IMV’s website. Following the presentations, the webcasts will be archived for 90 days and a copy of the presentations will remain available in the same section of the website.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at www.imv-inc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190325005122/en/
Investor Relations:Marc Jasmin, IMV Senior Director, Investor Relations and CommunicationsO: (902) 492-1819 ext : 1042M: (514) 617-9481E: mjasmin@imv-inc.com
Media:Andrea Cohen, Sam Brown Inc.T: (917) 209-7163E: andreacohen@sambrown.com
1 Year IMV Chart |
1 Month IMV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
